Continuous biomanufacturing – where are we now?

The biopharmaceutical industry is driven by the need to increase production and reduce costs, while maintaining product quality – and has increasingly been focused on intensification of processes to accomplish this goal. In this article, European Pharmaceutical Review’s Hannah Balfour summarises the potential benefits of implementing continuous bioprocessing and manufacturing as a method of process intensification, the current state of continuous process implementation and some ongoing challenges.

BIOPHARMACEUTICALS are a $331 billion industry,1 known for their precision, innovativeness and life-changing potential; however, stringent regulations and complex bioproduction methods that result in high manufacturing and product costs continue to limit the growth of this otherwise thriving sector.

To cut expenditure and complexity, as well as enhance process efficiency for large-scale biologics manufacturing, the industry is investing in the R&D of intensified bioprocesses. One such method under development is continuous biomanufacturing – the production of finished biopharmaceuticals using an uninterrupted process, consisting of an integrated sequence of more than one unit operation.